ClinPhone, a Clinical Technology Organization (CTO) and Cytel Inc., statistical experts in adaptive clinical trials, announced a partnership that unites expertise and clinical technologies
ClinPhone and Cytel – A New Partnership Delivering Complete Solutions for Adaptive Clinical Trials
(Nottingham, UK and Cambridge, USA 2 July 2008). ClinPhone, the world’s largest Clinical Technology Organization (CTO) and Cytel Inc., leading statistical experts in adaptive clinical trials, announced today a unique partnership that unites Cytel’s validated adaptive trial statistical and computational expertise with ClinPhone’s robust suite of clinical technologies and operational know-how.
This new partnership offers sponsors the combined expertise of the two organizations in successful design, planning and implementation of adaptive and other complex study designs. ClinPhone-Cytel adaptive trial solutions are tailored to the requirements and objectives of each individual clinical development program. This integrated service provides all the essential components for adaptive trial planning and implementation, including study design consulting, trial simulations, supplies planning and management, clinical data collection, randomization, trial supply management, data analysis and reporting.
Adaptive Clinical Trials (ACTs) refer to clinical studies that use accumulating response data to optimize pre-determined aspects of the study design without undermining the validity and integrity of the trial. By making mid-course adjustments to the trial, adaptive trials increase the ability to answer the study’s key research objectives, and improve the likelihood of a successful outcome. ClinPhone-Cytel solutions combine the innovative statistical techniques and trial technology advances that make designing and conducting adaptive trials practical for sponsor organizations of all sizes.
Irving Dark, Cytel’s Vice President of Clinical Research Services explains, “The ClinPhone-Cytel collaboration provides sponsors with the full-service offering needed for successful Adaptive Clinical Trials. This partnership underscores our commitment to be the leader in innovative trial design and implementation services.”
Dr. Bill Byrom, Vice President, Product Strategy and Marketing of ClinPhone comments, “Technology plays a central role in delivering these types of studies, and Cytel and ClinPhone together are leading the way in offering integrated services that provide a comprehensive solution for the sponsor wishing to benefit from the power of adaptive trials.”
To learn more about ClinPhone’s clinical trial technology solutions, please visit www.clinphone.com, or alternatively e-mail [email protected].
To learn more about Cytel Inc, please visit www.cytel.com, or alternatively e-mail [email protected].
About ClinPhone
ClinPhone plc is the world’s largest Clinical Technology Organization (CTO) with an unrivaled track record of innovation in the development of clinical trial technology. Headquartered in Nottingham UK with offices around the world, ClinPhone works with leading global biotechnology organizations, pharmaceutical companies and Contract Research Organizations (CROs).
ClinPhone is the largest and most accomplished CTO with experience in over 2,000 clinical trials spanning 88 countries and 71 languages. The Company’s experience includes Phase I to Phase IV studies, ranging from single center studies with 20 patients to “mega trials” with over 40,000 patients.
ClinPhone’s product portfolio, consisting of software and services, is backed by continuous research and investment in the latest technologies, coupled with extensive in-depth clinical industry experience. Its industry-leading software solutions include electronic data capture (EDC) and clinical trial management systems (CTMS), which can be licensed or implemented as hosted solutions. Delivered via its renowned Interactive Voice Response (IVR) and Interactive Web Response (IWR) platform, ClinPhone offers randomization, trial supply management, trial supply simulation, electronic patient reported outcomes (ePRO), and patient recruitment solutions.
ClinPhone’s products can integrate, taking the pain out of juggling and managing multiple sources of disparate information. This approach provides more control over data, improves data integrity and streamlines the data validation process.
About Cytel
Cytel pioneered the statistical science and computational technology of adaptive clinical trials. Benefiting both sponsors and patients, Cytel has designed more validated adaptive trials than anyone else.
Biopharmaceutical and device companies of all sizes turn to the clinical study planning, simulation and implementation experience of Cytel. Cytel experts have trained thousands of health sciences industry biostatisticians, clinicians, and regulatory staff in the latest trial design techniques.
Cytel’s Pharmaceutical Research Services place this clinical study innovation experience at the disposal of your research and development programs. From trial simulation and process development to independent data assessment and regulatory review, Cytel stands with you every step of the way.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.